Newborn screening for cystic fibrosis

Area of Science:

• Pediatrics
• Genetics
• Public Health

Background:

• Newborn screening for cystic fibrosis (CF) is now a global standard.
• The expansion of CF screening has highlighted new challenges for healthcare providers.
• Existing literature identifies these challenges and proposes management strategies.

Purpose of the Study:

• To review recent publications on newborn screening for cystic fibrosis.
• To provide an overview of challenges encountered in CF screening programs.
• To offer insights and management ideas for healthcare providers.

Main Methods:

• Systematic review of publications on newborn screening for CF.
• Analysis of challenges related to DNA mutation analysis, carrier detection, and inconclusive diagnoses.
• Examination of early findings in CF-related metabolic syndrome (CRMS) and CF pathophysiology.

Main Results:

• Newborn screening algorithms primarily use DNA mutation analysis.
• Expanded screening has revealed challenges in carrier detection and diagnosis.
• The natural history of CRMS is unpredictable, and optimal CF therapy in infants requires further study.

Conclusions:

• Newborn screening enables early identification and treatment of CF.
• While no single optimal screening approach exists, findings on sweat testing, carrier detection, and pathophysiology are beneficial.
• Continued research is needed to establish optimal therapies and clinical outcome recommendations for infants identified through newborn screening.